Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Predicting the risk of cardiovascular disease in HIV-infected patients : the data collection on adverse effects of anti-HIV drugs study. / Friis-Møller, Nina; Thiébaut, Rodolphe; Reiss, Peter; Weber, Rainer; Monforte, Antonella D'Arminio; De Wit, Stephane; El-Sadr, Wafaa; Fontas, Eric; Worm, Signe; Kirk, Ole; Phillips, Andrew; Sabin, Caroline A; Lundgren, Jens D; Law, Matthew G; DAD study group (Lars Østergaard, member).

In: European Journal of Preventive Cardiology, Vol. 17, No. 5, 10.2010, p. 491-501.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Friis-Møller, N, Thiébaut, R, Reiss, P, Weber, R, Monforte, ADA, De Wit, S, El-Sadr, W, Fontas, E, Worm, S, Kirk, O, Phillips, A, Sabin, CA, Lundgren, JD, Law, MG & DAD study group (Lars Østergaard, member) 2010, 'Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study', European Journal of Preventive Cardiology, vol. 17, no. 5, pp. 491-501. https://doi.org/10.1097/HJR.0b013e328336a150

APA

Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., Monforte, A. DA., De Wit, S., ... DAD study group (Lars Østergaard, member) (2010). Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. European Journal of Preventive Cardiology, 17(5), 491-501. https://doi.org/10.1097/HJR.0b013e328336a150

CBE

Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte ADA, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG, DAD study group (Lars Østergaard, member). 2010. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. European Journal of Preventive Cardiology. 17(5):491-501. https://doi.org/10.1097/HJR.0b013e328336a150

MLA

Vancouver

Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte ADA, De Wit S et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. European Journal of Preventive Cardiology. 2010 Oct;17(5):491-501. https://doi.org/10.1097/HJR.0b013e328336a150

Author

Friis-Møller, Nina ; Thiébaut, Rodolphe ; Reiss, Peter ; Weber, Rainer ; Monforte, Antonella D'Arminio ; De Wit, Stephane ; El-Sadr, Wafaa ; Fontas, Eric ; Worm, Signe ; Kirk, Ole ; Phillips, Andrew ; Sabin, Caroline A ; Lundgren, Jens D ; Law, Matthew G ; DAD study group (Lars Østergaard, member). / Predicting the risk of cardiovascular disease in HIV-infected patients : the data collection on adverse effects of anti-HIV drugs study. In: European Journal of Preventive Cardiology. 2010 ; Vol. 17, No. 5. pp. 491-501.

Bibtex

@article{997919111f584cbeb7b2dcbc5d6b2a00,
title = "Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study",
abstract = "AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients.METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score.CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.",
keywords = "Adult, Anti-HIV Agents, Argentina, Australia, Coronary Disease, Drug Therapy, Combination, Europe, Female, HIV Infections, Humans, Male, Middle Aged, Models, Statistical, Myocardial Infarction, Prospective Studies, Reproducibility of Results, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome",
author = "Nina Friis-M{\o}ller and Rodolphe Thi{\'e}baut and Peter Reiss and Rainer Weber and Monforte, {Antonella D'Arminio} and {De Wit}, Stephane and Wafaa El-Sadr and Eric Fontas and Signe Worm and Ole Kirk and Andrew Phillips and Sabin, {Caroline A} and Lundgren, {Jens D} and Law, {Matthew G} and {DAD study group (Lars {\O}stergaard, member)} and {\O}stergaard, {Lars J{\o}rgen}",
year = "2010",
month = "10",
doi = "10.1097/HJR.0b013e328336a150",
language = "English",
volume = "17",
pages = "491--501",
journal = "European Journal of Preventive Cardiology",
issn = "2047-4873",
publisher = "SAGE Publications",
number = "5",

}

RIS

TY - JOUR

T1 - Predicting the risk of cardiovascular disease in HIV-infected patients

T2 - the data collection on adverse effects of anti-HIV drugs study

AU - Friis-Møller, Nina

AU - Thiébaut, Rodolphe

AU - Reiss, Peter

AU - Weber, Rainer

AU - Monforte, Antonella D'Arminio

AU - De Wit, Stephane

AU - El-Sadr, Wafaa

AU - Fontas, Eric

AU - Worm, Signe

AU - Kirk, Ole

AU - Phillips, Andrew

AU - Sabin, Caroline A

AU - Lundgren, Jens D

AU - Law, Matthew G

AU - DAD study group (Lars Østergaard, member)

A2 - Østergaard, Lars Jørgen

PY - 2010/10

Y1 - 2010/10

N2 - AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients.METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score.CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.

AB - AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients.METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score.CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.

KW - Adult

KW - Anti-HIV Agents

KW - Argentina

KW - Australia

KW - Coronary Disease

KW - Drug Therapy, Combination

KW - Europe

KW - Female

KW - HIV Infections

KW - Humans

KW - Male

KW - Middle Aged

KW - Models, Statistical

KW - Myocardial Infarction

KW - Prospective Studies

KW - Reproducibility of Results

KW - Risk Assessment

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1097/HJR.0b013e328336a150

DO - 10.1097/HJR.0b013e328336a150

M3 - Journal article

C2 - 20543702

VL - 17

SP - 491

EP - 501

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

SN - 2047-4873

IS - 5

ER -